BeStock  
Stocks › Biotechnology › LXRX

Lexicon Pharmaceuticals LXRX

US equityMarket cap rank #3424Biotechnology
$1.76 +$0.01 (+0.57%)
Pre-market · Oct 8, 9:00 am ET · After hours $1.76 0.00%
Open$1.73
Prev close$1.75
Day range$1.71 – $1.77
Volume1.10M
Market cap$783.12M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$692,000.00-97.6% YoY
Operating profit-$26.54M-810.4% YoY
Net profit-$31.78M-1,077.1% YoY
Diluted EPS-$0.07-800.0% YoY
Free cash flow-$9.19M-154.1% YoY
Operating cash flow-$9.19M

Revenue, last 8 quarters

$1.8MSep '24$26.6MDec '24$1.3MMar '25$28.9MJun '25$14.2MSep '25$5.5MDec '25$21.1MMar '26$692.0KJun '26

Net profit, last 8 quarters

$-64.8MSep '24$-33.8MDec '24$-25.3MMar '25$3.3MJun '25$-12.8MSep '25$-15.5MDec '25$-1.0MMar '26$-31.8MJun '26

Diluted EPS by quarter

-0.18Sep '24-0.09Dec '24-0.07Mar '250.01Jun '25-0.04Sep '25-0.04Dec '250.00Mar '26-0.07Jun '26

Free cash flow by quarter

$-53.9MSep '24$-22.0MDec '24$-43.8MMar '25$17.0MJun '25$-23.8MSep '25$-17.2MDec '25$-14.7MMar '26$-9.2MJun '26

Annual revenue

$24.0MFY20$298.0KFY21$139.0KFY22$1.2MFY23$31.1MFY24$49.8MFY25

Profitability & balance sheet

Gross margin99.1%
Operating margin-131.4%
Net margin-147.4%
Return on equity-40.2%
Return on assets-25.7%
Return on invested capital-28.0%
Current ratio13.37
Liabilities / assets30.2%
Cash & investments$190.61M
Total debt$57.64M
Net cash (debt)$132.97M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $692,000.00 $21.10M $49.80M $5.49M $14.18M
Total Operating Revenue $692,000.00 $21.10M $49.80M $5.49M $14.18M
Cost of Revenue $39,000.00 $108,000.00 $274,000.00 $201,000.00 $10,000.00
Gross Profit $653,000.00 $20.99M $49.53M $5.29M $14.17M
Operating Expense $27.19M $21.99M $98.44M $20.07M $26.36M
Selling and Admin Expenses $9.75M $9.23M $37.32M $8.76M $7.60M
Research & Development $17.44M $12.76M $61.12M $11.32M $18.76M
Operating Profit -$26.54M -$996,000.00 -$48.91M -$14.78M -$12.19M
Net Non-Operating Interest Income (Expense) -$886,000.00 -$47,000.00 -$1.43M -$750,000.00 -$582,000.00
Non-Operating Interest Income $1.72M $1.54M $6.91M $1.28M $1.57M
Non-Operating Interest Expense $2.61M $1.59M $8.34M $2.03M $2.16M
Other Income (Expense) -$4.35M – – – –
Special Income (Charges) -$4.35M – – – –
-Less:Other Special Charges $4.35M – – – –
Pretax Profit -$31.78M -$1.04M -$50.34M -$15.53M -$12.77M
Net Profit -$31.78M -$1.04M -$50.34M -$15.53M -$12.77M
Profit from Continuing Operations -$31.78M -$1.04M -$50.34M -$15.53M -$12.77M
Net Income to Parent Company -$31.78M -$1.04M -$50.34M -$15.53M -$12.77M
Net Income to Common Stockholders -$31.78M -$1.04M -$50.34M -$15.53M -$12.77M
Basic EPS -$0.07 $0.00 -$0.14 -$0.04 -$0.04
Diluted EPS -$0.07 $0.00 -$0.14 -$0.04 -$0.04

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $250.06M $268.82M $184.99M $184.99M $205.93M
Total Current Assets $196.58M $186.03M $101.90M $101.90M $122.53M
Cash and Cash Equivalents & Short-Term Investments $190.61M $170.66M $96.23M $96.23M $115.95M
-Cash and Cash Equivalents $40.92M $38.09M $34.33M $34.33M $49.66M
-Short Term Investments $149.69M $132.57M $61.90M $61.90M $66.29M
Receivables $1.64M $11.78M $2.38M $2.38M $2.33M
-Accounts Receivable $1.64M $11.78M $2.38M $2.38M $2.33M
Inventory $1.20M $276,000.00 $281,000.00 $281,000.00 $158,000.00
Other Current Assets $3.13M $3.32M $3.00M $3.00M $4.09M
Total Non-Current Assets $53.48M $82.79M $83.09M $83.09M $83.40M
Net PPE $8.57M $8.88M $9.18M $9.18M $9.49M
-Gross PPE $11.49M $11.69M $11.89M $11.89M $12.08M
-Accumulated Depreciation -$2.92M -$2.82M -$2.71M -$2.71M -$2.59M
Goodwill and Other Intangible Assets $44.54M $44.54M $44.54M $44.54M $44.54M
-Goodwill $44.54M $44.54M $44.54M $44.54M $44.54M
Other Non-Current Assets $368,000.00 $29.37M $29.37M $29.37M $29.37M
Total Liabilities $75.54M $65.96M $77.45M $77.45M $85.77M
Total Current Liabilities $14.71M $9.90M $20.87M $20.87M $21.72M
Payables $2.34M $3.00M $3.08M $3.08M $3.80M
-Accounts Payable $2.34M $3.00M $3.08M $3.08M $3.80M
Current Accrued Expenses $6.83M $2.51M $5.13M $5.13M $7.19M
Short-Term Debt and Capital Lease Obligation $1.64M $1.64M $6.24M $6.24M $1.64M
-Current Capital Lease Obligation $1.64M $1.64M $1.64M $1.64M $1.64M
Total Non-Current Liabilities $60.83M $56.07M $56.58M $56.58M $64.05M
Long Term Debt and Capital Lease Obligation $57.64M $56.07M $56.58M $56.58M $56.51M
-Long Term Debt $51.44M $49.68M $49.41M $49.41M $56.51M
-Long Term Capital Lease Obligation $6.20M $6.38M $7.17M $7.17M –
Other Non-Current Liabilities $3.19M – – – $7.54M
Total Equity $174.53M $202.86M $107.54M $107.54M $120.16M
Stockholders' Equity $174.53M $202.86M $107.54M $107.54M $120.16M
Capital Stock $447,000.00 $430,000.00 $366,000.00 $366,000.00 $366,000.00
-Common Stock $447,000.00 $426,000.00 $366,000.00 $366,000.00 $366,000.00
-Preferred Stock $0.00 $4,000.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $2.23B $2.22B $2.13B $2.13B $2.13B
Retained Earnings -$2.05B -$2.02B -$2.02B -$2.02B -$2.00B
Less: Treasury Stock $2.84M $2.84M $5.19M $5.19M $5.19M
Gains/Losses Not Affecting Retained Earnings -$204,000.00 -$130,000.00 $30,000.00 $30,000.00 $29,000.00
-Current Debt – – $4.60M $4.60M –
Current Deferred Liabilities – – – – $4.30M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$9.19M -$14.73M -$67.85M -$17.23M -$23.83M
Net cash flow from continuing operations -$9.19M -$14.73M -$67.85M -$17.23M -$23.83M
Net Income from Continuing Operations -$31.78M -$1.04M -$50.34M -$15.53M -$12.77M
Depreciation & Depletion & Amortization $102,000.00 $110,000.00 $621,000.00 $118,000.00 $151,000.00
Other Non-Cash Items $1.01M $100,000.00 -$42,000.00 $332,000.00 $384,000.00
Change in Working Capital $14.51M -$16.41M -$26.89M -$4.55M -$14.31M
-Change in Receivables $10.14M -$9.40M $1.09M -$50,000.00 -$151,000.00
-Change in Inventory -$920,000.00 $5,000.00 -$50,000.00 -$123,000.00 $10,000.00
-Change in Prepaid Assets $191,000.00 -$319,000.00 $1.53M $1.08M -$358,000.00
-Change in Payables and Accrued Expense $4.90M -$6.90M -$30.22M -$5.65M -$14.00M
-Change in Other Current Assets $202,000.00 $195,000.00 $757,000.00 $190,000.00 $191,000.00
Net cash flow from investing -$16.46M -$70.26M $113.02M $4.83M $52.13M
Net Cash Flow from Continuing Investing Activities -$16.46M -$70.26M $113.02M $4.83M $52.13M
Net Investment Purchase and Sale -$16.46M -$70.26M $113.02M $4.83M $52.13M
Financing Cash Flow -$512,000.00 $88.76M -$48.50M -$2.93M $0.00
Net Cash Flow from Continuing Financing Activities -$512,000.00 $88.76M -$48.50M -$2.93M $0.00
Net Issuance Payments Of Debt $739,000.00 -$5.00M -$48.00M -$3.00M $0.00
Net Common Stock Issuance $1.02M $70.05M -$572,000.00 $0.00 -$572,000.00
Net Preferred Stock Issuance $0.00 $26.55M $0.00 $0.00 $0.00
Net Other Financing Charges -$2.27M -$2.84M – – –
Ending Cash Balance $40.92M $67.09M $63.33M $63.33M $78.66M
Net Change in Cash -$26.17M $3.76M -$3.33M -$15.33M $28.29M
Beginning Cash Balance $67.09M $63.33M $66.66M $78.66M $50.36M
Free Cash Flow -$9.19M -$14.73M -$67.85M -$17.23M -$23.83M
Net PPE Purchase and Sale – – $0.00 $0.00 –
Proceeds from Stock Option Exercised – – $73,000.00 – –

Discussion

No comments yet — be the first to weigh in on LXRX.

Leave a comment

Scroll to Top